180388-71-0 Usage
Chemical class
Phenothiazine derivatives It belongs to a group of chemical compounds derived from phenothiazine, which are often used in pharmaceutical applications.
Primary uses
Pharmaceutical field This compound is mainly used in the pharmaceutical industry for its potential therapeutic effects.
Therapeutic properties
Antipsychotic and neuroleptic It has the potential to treat certain mental health disorders by helping to manage symptoms such as hallucinations, delusions, and thought disorders.
Additional effects
Antiemetic and antihistaminic The compound can also help to alleviate symptoms of nausea and vomiting, as well as counteract the effects of histamine release in the body.
Precautions
Complex structure and potential side effects Due to its intricate chemical structure and possible adverse effects, this compound should be used with caution.
Supervision
Healthcare professional To ensure safe and effective use, it is important that this compound is administered under the guidance and supervision of a qualified healthcare professional.
Ongoing research
Mechanism of action and therapeutic applications The specific way in which this compound works and its potential uses in treating various conditions are still being studied and explored by researchers.
Check Digit Verification of cas no
The CAS Registry Mumber 180388-71-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,8,0,3,8 and 8 respectively; the second part has 2 digits, 7 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 180388-71:
(8*1)+(7*8)+(6*0)+(5*3)+(4*8)+(3*8)+(2*7)+(1*1)=150
150 % 10 = 0
So 180388-71-0 is a valid CAS Registry Number.
180388-71-0Relevant articles and documents
Reengineered tricyclic anti-cancer agents
Kastrinsky, David B.,Sangodkar, Jaya,Zaware, Nilesh,Izadmehr, Sudeh,Dhawan, Neil S.,Narla, Goutham,Ohlmeyer, Michael
, p. 6528 - 6534 (2015/10/05)
The phenothiazine and dibenzazepine tricyclics are potent neurotropic drugs with a documented but underutilized anti-cancer side effect. Reengineering these agents (TFP, CPZ, CIP) by replacing the basic amine with a neutral polar functional group (e.g., RTC-1, RTC-2) abrogated their CNS effects as demonstrated by in vitro pharmacological assays and in vivo behavioral models. Further optimization generated several phenothiazines and dibenzazepines with improved anti-cancer potency, exemplified by RTC-5. This new lead demonstrated efficacy against a xenograft model of an EGFR driven cancer without the neurotropic effects exhibited by the parent molecules. Its effects were attributed to concomitant negative regulation of PI3K-AKT and RAS-ERK signaling.